Tuesday, June 15, 2021
Mistargeted therapies can cause serious side effects and clinical failures. Learn about using the Membrane Proteome Array to identify off-target reactivities of antibody and cell therapies and the importance of these data for lead selection and regulatory submissions.
- Re-examine the long-held assumption that antibodies are exquisitely specific
- Learn what to do next if your molecule shows detectable off-target binding
- Discover how Membrane Proteome Array specificity data is used to satisfy regulatory requirements
We share your commitment to developing therapeutics for difficult-to-treat diseases. With 20 years of experience, our research team is dedicated to helping programs like yours succeed.